<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Redox Biol</journal-id><journal-id journal-id-type="iso-abbrev">Redox Biol</journal-id><journal-title-group><journal-title>Redox Biology</journal-title></journal-title-group><issn pub-type="epub">2213-2317</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39657365</article-id><article-id pub-id-type="pmc">PMC11681892</article-id><article-id pub-id-type="pii">S2213-2317(24)00438-5</article-id><article-id pub-id-type="doi">10.1016/j.redox.2024.103460</article-id><article-id pub-id-type="publisher-id">103460</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Zou</surname><given-names>Qiuming</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Zhou</surname><given-names>Xiaofeng</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Lai</surname><given-names>Jianqin</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Zhou</surname><given-names>Haixia</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Su</surname><given-names>Jinxuan</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Zhang</surname><given-names>Zhijing</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Zhuang</surname><given-names>Xiaosong</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Liu</surname><given-names>Lili</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Yuan</surname><given-names>Ruijie</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Li</surname><given-names>Sijia</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Yang</surname><given-names>Siyu</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Qu</surname><given-names>Xinyi</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Feng</surname><given-names>Jiezhu</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Liu</surname><given-names>Yongqi</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>Li</surname><given-names>Zisheng</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au16"><name><surname>Huang</surname><given-names>Shiting</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au17"><name><surname>Shi</surname><given-names>Zhi</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au18"><name><surname>Yan</surname><given-names>Yu</given-names></name><email>yanyu@jnu.edu.cn</email><xref rid="aff6" ref-type="aff">f</xref><xref rid="cor2" ref-type="corresp">&#x0204e;&#x0204e;</xref></contrib><contrib contrib-type="author" id="au19"><name><surname>Zheng</surname><given-names>Zhiming</given-names></name><email>zhiming0119@126.com</email><xref rid="aff7" ref-type="aff">g</xref><xref rid="cor3" ref-type="corresp">&#x0204e;&#x0204e;&#x0204e;</xref></contrib><contrib contrib-type="author" id="au20"><name><surname>Ye</surname><given-names>Wencai</given-names></name><email>chywc@aliyun.com</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor4" ref-type="corresp">&#x0204e;&#x0204e;&#x0204e;&#x0204e;</xref></contrib><contrib contrib-type="author" id="au21"><name><surname>Qi</surname><given-names>Qi</given-names></name><email>qiqikc@jnu.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff1"><label>a</label>State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, China</aff><aff id="aff2"><label>b</label>Department of Gastrointestinal Surgery, Guangzhou First People's Hospital, Guangzhou, 510180, China</aff><aff id="aff3"><label>c</label>State Key Laboratory of Bioactive Molecules and Druggability Assessment, Center for Bioactive Natural Molecules and Innovative Drugs Research, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China</aff><aff id="aff4"><label>d</label>School of Medicine, South China University of Technology, Guangzhou, 510006, China</aff><aff id="aff5"><label>e</label>Department of Cell Biology &#x00026; Institute of Biomedicine, Guangdong Provincial Biotechnology &#x00026; Engineering Technology Research Center, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Genomic Medicine Engineering Research Center of Ministry of Education, MOE Key Laboratory of Tumor Molecular Biology, National Engineering Research Center of Genetic Medicine, State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China</aff><aff id="aff6"><label>f</label>Functional Experimental Teaching Center, School of Medicine, Jinan University, Guangzhou, 510632, China</aff><aff id="aff7"><label>g</label>Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding authors. <email>qiqikc@jnu.edu.cn</email></corresp><corresp id="cor2"><label>&#x0204e;&#x0204e;</label>Corresponding author. <email>yanyu@jnu.edu.cn</email></corresp><corresp id="cor3"><label>&#x0204e;&#x0204e;&#x0204e;</label>Corresponding authors. <email>zhiming0119@126.com</email></corresp><corresp id="cor4"><label>&#x0204e;&#x0204e;&#x0204e;&#x0204e;</label>Corresponding author. <email>chywc@aliyun.com</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">These authors contributed equally to this study.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>05</day><month>12</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>12</month><year>2024</year></pub-date><volume>79</volume><elocation-id>103460</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>4</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and adolescents worldwide. Identification of novel therapeutic targets and development of targeted drugs are one of the most feasible strategies for OS treatment. Ferroptosis, a recently discovered mode of programmed cell death, has been implicated as a potential strategy for cancer therapy. Sulforaphane (SFN), the main bioactive compound derived from cruciferous vegetables, has shown potential anti-cancer effects with negligible toxicity. However, the role of ferroptosis in the effect of SFN on OS remains unknown. In the present study, we found that SFN acted as a potent ferroptosis inducer in OS, which was demonstrated by various inhibitors of cell death. The SFN-induced ferroptotic cell death was characterized by elevated ROS levels, lipid peroxidation, and GSH depletion, which was dependent on decreased levels of SLC7A11. Mechanically, SFN directly targeted p62 protein and enhanced p62/SLC7A11 protein-protein interaction, thereby promoting the lysosomal degradation of SLC7A11 and triggering ferroptosis. Notably, both subcutaneous and intratibial OS models in nude mice confirmed the ferroptosis associated anti-cancer efficacy of SFN <italic>in vivo</italic>. Hence, our findings demonstrate that SFN exerts its anti-cancer effects through inducing SLC7A11-dependent ferroptosis in OS, providing compelling evidence for the application of SFN in OS treatment.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="ga1"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Ferroptosis</kwd><kwd>Sulforaphane</kwd><kwd>p62</kwd><kwd>SLC7A11</kwd><kwd>Osteosarcoma</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Osteosarcoma (OS), accounting for approximately 56&#x000a0;% of bone sarcomas, is the most malignant bone tumor, primarily afflicting children, adolescents, and young adults, with a median age of 16 years [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. The current standard of care for OS includes extensive surgical resection, neoadjuvant chemotherapy, and adjuvant chemotherapy [<xref rid="bib3" ref-type="bibr">3</xref>], which has improved survival rates and increased the potential for limb preservation. However, the long-term administration of chemotherapy drugs takes a significant toll on normal tissues, particularly the heart, liver and kidneys [<xref rid="bib4" ref-type="bibr">4</xref>]. Additionally, OS has a strong tendency for local invasion and early metastasis with a recurrent rate of 30&#x0223c;50&#x000a0;% [<xref rid="bib5" ref-type="bibr">5</xref>]. Therefore, it is crucial to identify new therapeutic targets and agents for the treatment of OS.</p><p id="p0015">Sulforaphane (SFN, <xref rid="fig1" ref-type="fig">Fig. 1</xref>A), an isothiocyanate derived from cruciferous vegetables, particularly broccoli sprouts [<xref rid="bib6" ref-type="bibr">6</xref>], has been revealed for its anti-tumor potential in various types of cancers with negligible toxicity [<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>], which is achieved through several mechanisms, such as inhibiting phase I enzymes that activate carcinogens, inducing nuclear factor erythroid 2-related factor 2 (Nrf2)-regulated genes of phase II detoxification enzymes, and triggering apoptotic cell death [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>]. Additionally, SFN has been found to suppress angiogenesis by regulating vascular endothelial growth factor and matrix metalloproteinase-2 [<xref rid="bib16" ref-type="bibr">16</xref>], as well as inhibiting metastasis [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Notably, SFN also can pass the blood-brain barrier and exert therapeutic effects against neurodegenerative diseases [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. However, the specific anti-cancer effects and mechanisms of SFN against OS remain incompletely understood.<fig id="fig1"><label>Fig. 1</label><caption><p><bold>Ferroptosis contributes to SFN-induced cell death in OS cells. (A)</bold> Chemical structure of sulforaphane (SFN). <bold>(B)</bold> 143B and SJSA-1&#x000a0;cells were subjected to varying concentrations of SFN for 24 or 48&#x000a0;h, and their viability was evaluated using the MTT assay. <bold>(C)</bold> Representative images of the colony formation and quantitative analysis. <bold>(D)</bold> 143B and SJSA-1&#x000a0;cells were treated with SFN (5&#x000a0;&#x003bc;M or 10&#x000a0;&#x003bc;M) with or without Fer-1 (5&#x000a0;&#x003bc;M) for 48&#x000a0;h, and cell viability was measured. <bold>(E)</bold> 143B and SJSA-1&#x000a0;cells were exposed to SFN for 12&#x000a0;h, followed by the analysis of ROS levels using a flow cytometer. <bold>(F)</bold> Lipid peroxidation levels were assessed using a flow cytometer after 143B and SJSA-1&#x000a0;cells were treated with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h. <bold>(G)</bold> 143B and SJSA-1&#x000a0;cells were treated with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h, and GSH levels were measured. <bold>(H)</bold> Transmission electronic microscopy was used to observe the ultrastructure of 143B cells. Cells in the SFN (10&#x000a0;&#x003bc;M, 12&#x000a0;h) group displayed mitochondrial shrinkage, increased mitochondrial membrane density, and reduced mitochondrial cristae. Red arrow: mitochondrial change in SFN-treated cells. Scale bar: 500&#x000a0;nm. <bold>(I)</bold> Western blotting was performed to detect the expression of ferroptosis-related proteins in osteosarcoma cells following SFN treatment. &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0020">Ferroptosis is a novel form of iron and ROS-dependent cell death distinct from cell death induced by autophagy and apoptosis [<xref rid="bib21" ref-type="bibr">21</xref>], which is characterized by cytological changes, including reduced or absent mitochondria cristae, a ruptured outer mitochondrial membrane, and a condensed mitochondrial membrane [<xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>]. The dysregulation of ferroptosis has been closely associated with various human cancers [<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. Accumulating evidence highlights the pivotal role of ferroptosis in tumor suppression and considers its induction as a new therapeutic strategy for cancer treatment [<xref rid="bib29" ref-type="bibr">[29]</xref>, <xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>]. However, the role of ferroptosis and its application in OS treatment remain poorly understood.</p><p id="p0025">It has been revealed that ferroptosis is regulated by several key factors, including SLC7A11 and GPX4 [<xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>]. SLC7A11, located on the cell membrane, imports extracellular cystine into the cell, which is subsequently converted to GSH [<xref rid="bib36" ref-type="bibr">36</xref>]. GPX4 utilizes GSH to reduce lipid hydroperoxides, thus inhibiting ferroptosis [<xref rid="bib32" ref-type="bibr">32</xref>]. As such, SLC7A11 acts as a suppressor of ferroptosis, and their inhibition can trigger ferroptosis [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib32" ref-type="bibr">32</xref>]. The expression and activity of SLC7A11 are regulated at multiple levels, encompassing both translational and posttranslational mechanisms. For translational regulation, SLC7A11 can be induced by Nrf2 and regulated by BAP1 and the methylation of histone H3 [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>]. Posttranslational regulation of SLC7A11 primarily involves the lysosomal system and proteasome pathway, which act synergistically or independently to maintain intracellular protein homeostasis, thereby ensuring the selective degradation of biomaterials in cells [<xref rid="bib39" ref-type="bibr">39</xref>]. Notably, OTUB1, a noncanonical deubiquitinase, has been shown to interact with SLC7A11 to prevent its degradation [<xref rid="bib40" ref-type="bibr">40</xref>]. The adhesion molecule CD44 variant (CD44v) serves as a binding partner, modulating SLC7A11 protein stability [<xref rid="bib41" ref-type="bibr">41</xref>]. However, the specific mechanisms and regulation of SLC7A11 in ferroptosis in OS remain largely unexplored.</p><p id="p0030">In the present study, we found that SFN acts as a potent ferroptosis inducer in OS and significantly blocks OS growth <italic>in vitro</italic> and <italic>in vivo</italic>. Further data indicated that SFN directly targets p62 protein and promotes the lysosomal degradation pathway of SLC7A11 through enhancing p62/SLC7A11 protein-protein interaction. These findings provide compelling evidence that targeting SLC7A11 is a promising strategy for OS treatment and lay the foundation for the application of SFN in OS therapy.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1</label><title>Cell culture</title><p id="p0035">Human OS cells (143B and SJSA-1) and HEK293T cells were obtained from the American Type Culture Collection (ATCC). 143B cells were cultured in MEM medium supplemented with 10&#x000a0;% fetal bovine serum (FBS) and 1&#x000a0;% penicillin-streptomycin (PS). SJSA-1&#x000a0;cells were cultured in RPMI-1640 medium with 10&#x000a0;% FBS and 1&#x000a0;% PS. HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10&#x000a0;% FBS and 1&#x000a0;% PS. All cells were maintained at 37&#x000a0;&#x000b0;C in a humidified incubator containing 5&#x000a0;% CO<sub>2</sub>.</p></sec><sec id="sec2.2"><label>2.2</label><title>Animal study</title><p id="p0040">All animal experiments were conducted in compliance with the protocols approved by the Use and Care of Animals Committee at Jinan University. A subcutaneous tumor-bearing nude mouse model was established by injecting 5&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> 143B cells into the flank of BALB/c nude mice. Six days post-injection, mice were randomly assigned to one of three groups and received intraperitoneal injection of either 200&#x000a0;&#x003bc;l of normal saline, SFN (25&#x000a0;mg/kg every two days), or SFN (50&#x000a0;mg/kg every two days). Tumor dimensions and body weight were recorded every two days following the initial drug administration. Tumor volume was calculated using the formula: (tumor long diameter&#x000a0;&#x000d7;&#x000a0;tumor short diameter<sup>2</sup>)/2. At the end of study, mice were euthanized, and tumors were collected for immunohistochemical (IHC) staining.</p><p id="p0045">For the intratibial xenograft model, BALB/c nude mice were anesthetized with 0.5&#x000a0;% pentobarbital sodium (ip, 200 &#x003bc;l/mouse). 143B cells (4&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>&#x000a0;cells/ml) suspended in PBS (25 &#x003bc;l/mice) were orthotopically injected into the proximal tibia. When tumors reached approximately 80&#x000a0;mm<sup>3</sup>, the tumor-bearing mice were randomly assigned to receive normal saline, Fer-1 (2&#x000a0;mg/kg), SFN (50&#x000a0;mg/kg), or SFN&#x000a0;+&#x000a0;Fer-1 every two days. Following the treatment, mice were euthanized, and tumor tissues were collected for further analysis.</p></sec><sec id="sec2.3"><label>2.3</label><title>Reagents and antibodies</title><p id="p0050">Sulforaphane (TRC-S699115) was acquired from Toronto Research Chemicals. Deferoxamine (HY-B0988), MG132 (HY-13259), Bafilomycin A1 (HY-100558), Ferrostatin-1 (HY-100579), Liproxstatin-1 (HY-12726), Necrostatin-1 (HY-15760), Z-VAD-FMK (HY-16658B), and chloroquine (HY-17589A) were purchased from MCE. Antibodies included anti-Ki67 (Servicebio, GB121141-100) and anti-GPX4 (59735), anti-SLC7A11 (12691), anti-&#x003b2;-actin (3700), anti-p62 (23214), anti-LC3B (3868), anti-rabbit IgG (H&#x000a0;+&#x000a0;L), Biotinylated Antibody (14708), and Anti-mouse IgG (H&#x000a0;+&#x000a0;L), Biotinylated Antibody (14709) from the Cell Signaling Technology.</p></sec><sec id="sec2.4"><label>2.4</label><title>Cell viability analysis</title><p id="p0055">Cell viability was assessed using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded in 96-well plates at a density of 5&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup>&#x000a0;cells per well, cultured for 24&#x000a0;h, and subsequently treated with SFN. Following incubation, the cells were exposed to 5&#x000a0;mg/ml MTT solution at 37&#x000a0;&#x000b0;C for 2&#x000a0;h. Formazan was dissolved in DMSO and optical density was read in a microplate reader with a wavelength of 595&#x000a0;nm.</p></sec><sec id="sec2.5"><label>2.5</label><title>Colony formation assay</title><p id="p0060">Cells were seeded in 6-well plates at a density of 1&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup>&#x000a0;cells per well. The culture medium with or without drugs was replenished every 2&#x02013;3 days. Colonies were fixed, stained by 0.1&#x000a0;% crystal violet, and colonies were quantified using ImageJ software.</p></sec><sec id="sec2.6"><label>2.6</label><title>Quantitative real-time PCR</title><p id="p0065">Total RNA was extracted using TRIzol (Invitrogen, CA, USA) and reverse transcribed using the TransScript All-in-One First-Strand cDNA Synthesis SuperMix (TransGen Biotech). For the analysis of mRNA expression, PerfectStart Green qPCR SuperMix (TransGen Biotech) was employed. The primers used are listed below: SLC7A11-F: GGGCATGTCTCTGACCATCT; SLC7A11-R: TCCCAATTCAGCATAAGACAAA; &#x003b2;-actin-F: ACTTAGTTGCGTTACACCCTTTCT; &#x003b2;-actin-R: GACTGCTGTCACCTTCACCGT.</p></sec><sec id="sec2.7"><label>2.7</label><title>ROS measurement</title><p id="p0070">Intracellular ROS levels were assessed using the DCFH-DA oxidative stress indicator (Beyotime, S0033) in accordance with the manufacturer's instructions. Specifically, cells were cultured in serum-free medium supplemented with DCFH-DA at 37&#x000a0;&#x000b0;C for 30&#x000a0;min. Subsequently, the cells were collected, and the fluorescence signals were measured by flow cytometry.</p></sec><sec id="sec2.8"><label>2.8</label><title>Analysis of lipid peroxidation</title><p id="p0075">The intracellular lipid peroxidation was quantified with MDA assay. MDA levels were determined using a Lipid Peroxidation MDA Assay Kit (Beyotime, S0131). For Liperfluo staining, cells were exposed to Liperfluo (10&#x000a0;&#x003bc;M, Dojindo, Japan) for 1&#x000a0;h at 37&#x000a0;&#x000b0;C, followed by trypsin digestion, and fluorescence intensity was measured by flow cytometer.</p></sec><sec id="sec2.9"><label>2.9</label><title>FerroOrange staining and GSH assay</title><p id="p0080">FerroOrange (Dojindo, Japan) is a fluorescent probe used for live-cell imaging of intracellular Fe<sup>2+</sup> ions. Live cells were incubated with FerroOrange for 1&#x000a0;h, and intracellular Fe<sup>2</sup>&#x0207a; levels were visualized using a confocal microscope. GSH levels were conducted using a GSH Assay Kit (Nanjing Jiancheng Bioengineering Institute, A006-2-1) in accordance with the provided instructions.</p></sec><sec id="sec2.10"><label>2.10</label><title>LysoTracker staining</title><p id="p0085">Cells were incubated with DMEM containing 100&#x000a0;nM LysoTracker Red DND-99 (Thermo Fisher Scientific, L7528) for 30&#x000a0;min at 37&#x000a0;&#x000b0;C. Subsequently, the cells were collected, and the fluorescence signals were analyzed using flow cytometry.</p></sec><sec id="sec2.11"><label>2.11</label><title>Immunoprecipitation (IP) and western blotting</title><p id="p0090">Cells were lysed in lysis buffer (150&#x000a0;mM NaCl, 0.5&#x000a0;% NP-40, 1&#x000a0;mM EDTA, 10&#x000a0;% glycerophosphate, 50&#x000a0;mM Tris-Cl, and a proteinase inhibitor cocktail). Following a 30&#x000a0;min incubation, the cellular lysates were separated by centrifugation at 12,000&#x000a0;rpm at 4&#x000a0;&#x000b0;C for 15&#x000a0;min. The resultant supernatant was then subjected to incubation with 20&#x000a0;&#x003bc;l of protein A/G agarose beads and the specified antibody at 4&#x000a0;&#x000b0;C overnight. After extensive washing, the beads were eluted, fractionated via SDS-polyacrylamide gel electrophoresis, and subjected to immunoblotting analysis. The immunoblots were visualized using an electrochemiluminescence imaging system (Tanon, Shanghai, China).</p></sec><sec id="sec2.12"><label>2.12</label><title>Immunofluorescence staining</title><p id="p0095">Cells were seeded on glass coverslips and rinsed with PBS, followed by fixation with 3.7&#x000a0;% formaldehyde. After fixation, the cells were washed with PBS and permeabilized using 0.1&#x000a0;% Triton X-100 in PBS for 10&#x000a0;min. Next, a blocking buffer (5&#x000a0;% BSA in 0.1&#x000a0;% Triton/PBS) was applied for 1&#x000a0;h, followed by overnight incubation with specific antibodies. Subsequently, the cells were washed three times with PBS and incubated with fluorescent secondary antibodies (ThermoFisher Scientific) for 2&#x000a0;h. Nuclei were stained with 4&#x02019;,6-diamidino-2-phenylindole (DAPI, ThermoFisher Scientific), and fluorescence was observed using a confocal microscope (Zeiss).</p></sec><sec id="sec2.13"><label>2.13</label><title>Cellular thermal shift assay (CETSA)</title><p id="p0100">Cells were trypsinized and resuspended in PBS containing a protease and phosphatase inhibitor cocktail. The cell suspension was divided into eight fractions and heated at a gradient of temperatures for 3&#x000a0;min. Subsequently, the fractions were subjected to two cycles of freezing in liquid nitrogen and thawing at room temperature, followed by centrifugation at 12000&#x000a0;rpm for 20&#x000a0;min. The supernatant was collected and analyzed using western blot assay.</p></sec><sec id="sec2.14"><label>2.14</label><title>Molecular docking</title><p id="p0105">Molecular docking was conducted using AutoDock Vina 1.0.2. The crystal structure of p62 (PDB: <ext-link ext-link-type="PDB" xlink:href="https://www.rcsb.org/4MJS" id="intref0010">4MJS</ext-link>) and SLC7A11 (PDB: <ext-link ext-link-type="PDB" xlink:href="https://www.rcsb.org/8A9L" id="intref0015">8A9L</ext-link>) were obtained from the RCSB protein data bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/" id="intref0020">https://www.rcsb.org/</ext-link>). The structure of sulforaphane was retrieved from the PubChem database (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/" id="intref0025">https://pubchem.ncbi.nlm.nih.gov/</ext-link>). File transformations were performed using Open Babel software. Visualization of the most suitable complexes was performed using Discovery Studio 2021 Client and Pymol 2.2.0.</p></sec><sec id="sec2.15"><label>2.15</label><title>Microscale thermophoresis (MST)</title><p id="p0110">HEK293T cells were transfected with a p62-mCherry plasmid, after which the protein lysates were collected using RIPA lysis buffer. Subsequently, SFN was serially diluted with PBS to concentrations ranging from 50,000&#x02013;1.53&#x000a0;nM. The protein lysates were then treated with the SFN solutions for 5&#x000a0;min. The resulting mixtures were loaded into capillaries and subjected to MST measurements using a Monolith NT.115 instrument (Nanotemper, Munich, Germany).</p></sec><sec id="sec2.16"><label>2.16</label><title>Isothermal titration calorimetry (ITC)</title><p id="p0115">ITC measurements were conducted using a MicroCal PEAQ-ITC instrument (Malvern) at 25&#x000a0;&#x000b0;C in a buffer containing 50&#x000a0;mM HEPES (pH 7.5), 150&#x000a0;mM NaCl, and 2&#x000a0;mM DTT. SFN was gradually injected from the titration syringe into the p62 protein solution, with injections spaced 120&#x000a0;s apart and stirring at 750&#x000a0;rpm. The thermodynamic response was recorded in high-feedback mode, and the raw data were analyzed using the MicroCal PEAQ-ITC software.</p></sec><sec id="sec2.17"><label>2.17</label><title>Immunohistochemistry (IHC) and hematoxylin-eosin (H&#x00026;E) staining</title><p id="p0120">The tumors were fixed in 4&#x000a0;% paraformaldehyde overnight, followed by paraffin embedding. Sections (8&#x000a0;&#x003bc;m) were deparaffinized in xylene and rehydrated through a graded series of alcohols. Endogenous peroxidase activity was blocked by treatment with 3&#x000a0;% hydrogen peroxide for 5&#x000a0;min, and all slides were subjected to heat-induced antigen retrieval by boiling in 10&#x000a0;mM citrate buffer (pH 6.0) for 10&#x000a0;min. Specific primary antibodies were applied and the slides were subsequently counterstained with hematoxylin. For H&#x00026;E staining, the sections were immersed in hematoxylin for 3&#x000a0;min, rinsed with water for 30&#x000a0;min, and then stained with eosin for 3&#x000a0;min. Following dehydration in graded ethanol solutions, coverslips were mounted on the slides and examined using an optical microscope.</p></sec><sec id="sec2.18"><label>2.18</label><title>Statistical analysis</title><p id="p0125">Unpaired two-tailed Student's t-test and one- and two-way analysis of variance (ANOVA) were used to calculate P values by GraphPad Prism 8. The Tukey method was used to adjust multiple comparisons. Quantifications were performed from at least three independent experiments. All data represent by mean&#x000a0;&#x000b1;&#x000a0;SD except where specially indicated as mean&#x000a0;&#x000b1;&#x000a0;SEM in the figure legends. P&#x000a0;&#x0003c;&#x000a0;0.05 was considered significant.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>SFN induces ferroptosis in OS cells</title><p id="p0130">To fully achieve the anti-tumor efficacy of SFN in human OS, we firstly examine the cytotoxicity of SFN in 143B and SJSA-1 human OS cells. Data showed that SFN inhibited the proliferation of 143B and SJSA-1&#x000a0;cells in dose- and time-dependent manner (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B). Furthermore, colony formation assay demonstrated a significant reduction in the proliferative capacity of both 143B and SJSA-1&#x000a0;cells (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C).</p><p id="p0135">To identify the primary cell death type triggered by SFN, specific inhibitors of necroptosis, autophagy, apoptosis, and ferroptosis were employed. With the co-treatment of SFN/inhibitor, data showed that Nec-1 (necrostatin-1, necroptosis inhibitor), Z-VAD (Z-VAD-FMK, pan-caspase inhibitor), and CQ (chloroquine, autophagy inhibitor) could not prevent SFN-induced cell death in 143B and SJSA-1&#x000a0;cells (<xref rid="appsec2" ref-type="sec">Figs. S1A&#x02013;C</xref>). However, the ferroptosis inhibitors Fer-1 (ferrostatin-1), DFO (deferoxamine), and Lip-1 (liproxstatin-1) substantially rescued the cells from SFN-induced cell death (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D, <xref rid="appsec2" ref-type="sec">Figs. S1D and E</xref>), which indicated that ferroptosis was the predominant cell death form of OS cells treated by SFN. To further confirm the induction of ferroptosis in OS cells in response to SFN, we assessed key events associated with ferroptosis process, including ROS accumulation, GSH depletion, and lipid peroxidation. Data showed that SFN treatment led to elevated levels of ROS and increased lipid peroxidation (<xref rid="fig1" ref-type="fig">Fig. 1</xref>E and F), along with a significant reduction in GSH levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>G). Additionally, transmission electron microscopy (TEM) revealed morphological changes consistent with ferroptosis in SFN-treated cells, including altered mitochondrial structure, increased mitochondrial membrane density, and reduced or absent mitochondrial cristae (<xref rid="fig1" ref-type="fig">Fig. 1</xref>H). Moreover, western blotting analysis demonstrated that SFN treatment markedly reduced the expression levels of ferroptosis markers GPX4 and SLC7A11 in OS cells (<xref rid="fig1" ref-type="fig">Fig. 1</xref>I). These data indicate that SFN exerts potent pro-ferroptotic effect in OS cells.</p></sec><sec id="sec3.2"><label>3.2</label><title>SFN-mediated cytotoxicity in OS cells is dependent on ferroptosis</title><p id="p0140">To determine the role of ferroptosis in SFN-mediated inhibition of OS, a series of rescue experiments were conducted using the ferroptosis inhibitor Fer-1. Colony formation assay showed that with the treatment of Fer-1, SFN induced suppression of 143B and SJSA-1&#x000a0;cells was significantly abolished (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). Additionally, Fer-1 alleviated SFN-induced ROS accumulation, lipid peroxidation, and GSH depletion (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B&#x02013;D). Furthermore, FerroOrange fluorescent probe validated the intracellular Fe<sup>2+</sup> accumulation by SFN, as well as the abolishment of the increased Fe<sup>2+</sup> levels by Fer-1 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E). Moreover, Fer&#x02010;1 rescued the reduction of SLC7A11 and GPX4 induced by SFN (<xref rid="fig2" ref-type="fig">Fig. 2</xref>F). These findings demonstrate that SFN effectively induces ferroptosis, acting as the primary anti-tumor effect in OS.<fig id="fig2"><label>Fig. 2</label><caption><p><bold>Fer-1 reverses SFN-induced ferroptosis in OS cells. (A)</bold> Treatment of 143B and SJSA-1&#x000a0;cells with SFN (1&#x000a0;&#x003bc;M) with or without Fer-1 (1&#x000a0;&#x003bc;M), with representative results of colony formation and quantitative analysis. <bold>(B)</bold> Analysis of ROS levels in 143B and SJSA-1&#x000a0;cells treated with SFN (10&#x000a0;&#x003bc;M) with or without Fer-1 (5&#x000a0;&#x003bc;M). <bold>(C)</bold> Analysis of Liperfluo levels in 143B and SJSA-1&#x000a0;cells treated with SFN (10&#x000a0;&#x003bc;M) with or without Fer-1 (5&#x000a0;&#x003bc;M). <bold>(D)</bold> Detection of GSH levels in 143B and SJSA-1&#x000a0;cells treated with SFN (10&#x000a0;&#x003bc;M) with or without Fer-1 (5&#x000a0;&#x003bc;M). <bold>(E)</bold> Detection of intracellular Fe<sup>2+</sup> levels in 143B and SJSA-1&#x000a0;cells treated with SFN (10&#x000a0;&#x003bc;M) with or without Fer-1 (5&#x000a0;&#x003bc;M). Scale bar: 200&#x000a0;&#x003bc;m. <bold>(F)</bold> Western blotting to detect the expression of ferroptosis-related proteins in OS cells after 12&#x000a0;h treatment with SFN (10&#x000a0;&#x003bc;M) with or without Fer-1 (5&#x000a0;&#x003bc;M). &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec3.3"><label>3.3</label><title>SFN induces ferroptosis of OS cells through downregulation of SLC7A11</title><p id="p0145">Lipid peroxidation, the initiating step of ferroptosis, is characterized by decreased GSH which is a crucial antioxidant that helps role in maintaining the redox balance and defending against oxidative stress in cells [<xref rid="bib42" ref-type="bibr">42</xref>]. SLC7A11, a key component of the cystine-glutamate antiporter regulating GSH generation, was downregulated notably in SFN-treated OS cells, which was more prominent than GPX4 (<xref rid="fig1" ref-type="fig">Fig. 1</xref>I). Since SLC7A11 is the upstream regulator of GPX4, we further elucidate the role of SLC7A11 in the anti-cancer effect of SFN against OS. While overexpression of SLC7A11 did not affect cell proliferation (<xref rid="appsec2" ref-type="sec">Fig. S2A</xref>), it significantly attenuated SFN-induced inhibition of proliferation in OS cells (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A and B). Furthermore, SLC7A11 overexpression notably reversed SFN-induced changes in the ROS level, GSH level, and lipid peroxidation (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C&#x02013;E). Additionally, TEM and Fe<sup>2+</sup> FerroOrange fluorescent analysis showed that the SFN-induced morphological changes of ferroptosis and enhanced Fe<sup>2+</sup> levels could be abolished by overexpression of SLC7A11 (<xref rid="fig3" ref-type="fig">Fig. 3</xref>F and G). These results demonstrate the dependency of downregulation of SLC7A11 in SFN-induced ferroptosis in OS cells.<fig id="fig3"><label>Fig. 3</label><caption><p><bold>SLC7A11 is accounted for SFN-induced ferroptosis in OS cells. (A, B)</bold> Treatment of 143B (A) and SJSA-1 (B) cells with SFN for 48&#x000a0;h with or without overexpression of SLC7A11, followed by cell viability assay. <bold>(C)</bold> Treatment of 143B and SJSA-1&#x000a0;cells with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h with or without overexpression of SLC7A11, and subsequent assay of relative ROS levels. <bold>(D)</bold> Treatment of 143B and SJSA-1&#x000a0;cells with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h with or without overexpression of SLC7A11, followed by assay of relative GSH levels. <bold>(E)</bold> Treatment of 143B and SJSA-1&#x000a0;cells with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h with or without overexpression of SLC7A11, and subsequent assay of relative Liperfluo levels. <bold>(F)</bold> Treatment of 143B and SJSA-1&#x000a0;cells with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h with or without overexpression of SLC7A11, and image of transmission electronic microscopy. Red arrow: mitochondrial change in SFN-treated cells. Scale bar: 500&#x000a0;nm. <bold>(G)</bold> Treatment of 143B and SJSA-1&#x000a0;cells with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h with or without overexpression of SLC7A11, and subsequent assay of intracellular Fe<sup>2+</sup> levels. Scale bar: 200&#x000a0;&#x003bc;m &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec3.4"><label>3.4</label><title>SFN downregulates SLC7A11 through induction of its autolysosomal degradation in OS cells</title><p id="p0150">To explore the mechanism by which SFN decreases SLC7A11 expression, we first evaluated SLC7A11 mRNA levels in OS cells following SFN treatment. The results showed that SFN did not significantly reduce SLC7A11 mRNA levels in OS cells (<xref rid="appsec2" ref-type="sec">Fig. S2B</xref>), indicating that the reduction in SLC7A11 expression is independent of transcriptional inhibition. Subsequently, we investigated whether the SFN-induced downregulation of SLC7A11 was due to enhanced protein degradation by measuring the half-life of the SLC7A11 protein using cycloheximide (CHX) chase assay. Results showed that the half-life of endogenous SLC7A11 protein was significantly reduced in OS cells subjected to SFN treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A and B). Furthermore, to identify the degradation mechanism of SLC7A11, we treated cells with SFN in combination with either bafilomycin A1 (Baf-A1), a lysosomal fusion inhibitor, or MG132, a proteasomal inhibitor. Western blotting analysis revealed that MG132 did not block SFN-induced degradation of SLC7A11 (<xref rid="appsec2" ref-type="sec">Figs. S3A and B</xref>), whereas Baf-A1 completely inhibited it (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C and D), suggesting that SLC7A11 is degraded predominantly by lysosomal degradation. Furthermore, to assess the effect of SFN on lysosomal activation, we performed LysoTracker assays. The fluorescence intensity of the pH-sensitive dye LysoTracker Red increased significantly with SFN treatment, indicating enhanced lysosomal acidification (reduced pH) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>E). Additionally, SFN treatment significantly increased the autophagosome marker LC3II (<xref rid="fig4" ref-type="fig">Fig. 4</xref>F). Co-localization between SLC7A11 and the LysoTracker Red further supported enhanced interaction following <funding-source id="gs1">SFN</funding-source> treatment, which could be inhibited by Baf-A1 treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>G). Moreover, to further confirm the functional role of autophagy-lysosomal pathway in the activity of SFN against OS, a series of rescue experiments using Baf-A1 was performed. Results showed that Baf-A1 demonstrated restoration of cell proliferation in 143B and SJSA-1&#x000a0;cells treated with SFN (<xref rid="fig4" ref-type="fig">Fig. 4</xref>H). Baf-A1 also partially reversed SFN-induced ROS accumulation, GSH depletion, and lipid peroxidation in OS cells (<xref rid="fig4" ref-type="fig">Fig. 4</xref>I&#x02013;K). Collectively, these findings suggest that SFN promotes SLC7A11 degradation through the autophagy-lysosome pathway.<fig id="fig4"><label>Fig. 4</label><caption><p><bold>SFN downregulates SLC7A11 via autophagy-lysosome degradation in OS cells. (A, B)</bold> 143B (A) and SJSA-1 (B) cells treated with CHX (50&#x000a0;&#x003bc;g/ml) with or without SFN (5&#x000a0;&#x003bc;M), and collected at specified times. The cells were lysed, and the cell lysates were subsequently blotted with the indicated antibodies. <bold>(C, D)</bold> SLC7A11 expressions with SFN (10&#x000a0;&#x003bc;M) and Baf-A1 (200&#x000a0;nM) treatment in 143B (C) and SJSA-1 (D) cells. <bold>(E)</bold> 143B and SJSA-1&#x000a0;cells treated with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h. The cells were then loaded with LysoTracker Red reagent for 15&#x000a0;min. Fluorescence intensity was measured by flow cytometry. <bold>(F)</bold> Western blotting analysis of LC3B in 143B and SJSA-1&#x000a0;cells after treatment with indicated doses of SFN. <bold>(G)</bold> Representative image of the colocalization of SLC7A11 with lysosome in 143B and SJSA-1&#x000a0;cells. Scale bar: 20&#x000a0;&#x003bc;m. <bold>(H)</bold> 143B and SJSA-1&#x000a0;cells were treated with SFN (5&#x000a0;&#x003bc;M or 10&#x000a0;&#x003bc;M) with or without Baf-A1 (200&#x000a0;nM), and cell proliferation was analyzed. <bold>(I)</bold> 143B and SJSA-1&#x000a0;cells were treated with SFN (10&#x000a0;&#x003bc;M) with or without Baf-A1 (200&#x000a0;nM), and the ROS levels were analyzed. <bold>(J)</bold> 143B and SJSA-1&#x000a0;cells were treated with SFN (10&#x000a0;&#x003bc;M) with or without Baf-A1 (200&#x000a0;nM), and the GSH levels were detected. <bold>(K)</bold> 143B and SJSA-1&#x000a0;cells were treated with SFN (10&#x000a0;&#x003bc;M) with or without Baf-A1 (200&#x000a0;nM), and the Liperfluo levels were analyzed. &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec3.5"><label>3.5</label><title>SFN downregulates SLC7A11 via p62-dependent selective autophagy</title><p id="p0155">It has been reported that selective autophagic degradation is closely related ferroptosis [<xref rid="bib43" ref-type="bibr">43</xref>]. We further examined the potential role of some major autolysosomal proteins including autophagy-related protein 3 (ATG3), lysosome associated membrane protein 1 (LAMP1), LC3B, and p62 in selective autophagy related SLC7A11 degradation. Data from Co-IP assay showed that among these autophagy-related proteins, the adapter protein p62 selectively interacted with SLC7A11 in OS cells (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A; <xref rid="appsec2" ref-type="sec">Fig. S4</xref>), which was confirmed by pull-down assay with exogenous expressed proteins (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B). Subsequently, we further determine the role of p62 in SFN-induced downregulation of SLC7A11. As shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>C, silencing p62 reversed SFN-induced decrease in SLC7A11 protein levels (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C). Additionally, CHX assay also demonstrated that the degradation of SLC7A11 induced by SFN in OS cells was reversed by si-p62 treatment (<xref rid="appsec2" ref-type="sec">Fig. S5</xref>). Immunoprecipitation assay revealed that SFN treatment increased the binding of p62 to SLC7A11 in both 143B and SJSA-1&#x000a0;cells (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D). Immunofluorescence co-staining also showed a significant increase in the colocalization of SLC7A11 with p62 following SFN treatment (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E). To identify the binding domain of p62 responsible for its interaction with SLC7A11, we conducted truncation GST pull-down assay with p62 truncation variants [<xref rid="bib44" ref-type="bibr">44</xref>]. The results indicated that the PB1 domain of p62 is responsible for the interaction with SLC7A11 (<xref rid="fig5" ref-type="fig">Fig. 5</xref>F). These results indicate that p62 plays a crucial role in the degradation of SLC7A11.<fig id="fig5"><label>Fig. 5</label><caption><p><bold>SFN regulates SLC7A11 via p62 dependent selective autophagy. (A)</bold> Endogenous p62 was immunoprecipitated with SLC7A11 antibody and examined by immunoblotting. <bold>(B)</bold> Interaction between exogenous p62 and SLC7A11. HEK293T cells were co-transfected with indicated constructs. Cellular extracts were immunoprecipitated with FLAG Sepharose and immunoprecipitations were performed with antibodies against the indicated proteins. <bold>(C)</bold> Western blotting data from p62 siRNA assay, untreated or treated with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h. <bold>(D)</bold> Analysis of the interaction between SLC7A11 and p62. Cells left untreated or treated with SFN (10&#x000a0;&#x003bc;M) for 12&#x000a0;h. Equal amounts of cell lysates were subjected to immunoprecipitation (IP) with antibodies against SLC7A11 or control IgG and western blotted with the respective antibodies. <bold>(E)</bold> Representative image and colocalization efficiency were measured by ImageJ software of immunofluorescence staining in 143B and SJSA-1&#x000a0;cells for immunostaining of SLC7A11 (green) with p62 (red). The fluorescence-integrated density was measured by ImageJ software. Scale bar: 5&#x000a0;&#x003bc;m. <bold>(F)</bold> Identification of PB1 domain of p62 is responsible for the interaction with SLC7A11. Flag-SLC7A11 construct was cotransfected with various truncates of GST tagged p62 into HEK293T cells. Cell lysates were pulled down with glutathione beads and analyzed by western blotting. &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0035">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec3.6"><label>3.6</label><title>SFN directly binds to autophagic cargo adapter p62 in OS cells</title><p id="p0160">To elucidate the specific mechanism by which SFN regulates p62 and SLC7A11, we hypothesize that SFN might directly bind either p62 or SLC7A11, conferring the association between p62 and SLC7A11. To test this, we first conducted a molecular docking to achieve a binding profile of SFN and proteins. Data showed that a direct binding between SFN and p62 with the binding energy of &#x02212;4.31&#x000a0;kcal/mol, which is smaller than that of SFN and SLC7A11 (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A and B). Subsequently, we investigated the thermal stabilization of p62 upon SFN binding using the Cellular Thermal Shift Assay (CETSA) and found SFN significantly enhanced the thermal stability of p62 in OS cells (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C), while it had no effect on the stability of SLC7A11 (<xref rid="appsec2" ref-type="sec">Fig. S6</xref>). Furthermore, Drug Affinity Responsive Target Stability (DARTS) assay confirmed the binding of SFN to p62 (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D). For the quantified analysis of the binding of SFN and p62, Microscale Thermophoresis (MST) analysis showed a dose-dependent interaction of SFN and p62, with a dissociation constant (Kd) of 15.546&#x000a0;&#x000b1;&#x000a0;3.929 &#x003bc;&#x0041c; (<xref rid="fig6" ref-type="fig">Fig. 6</xref>E) which was similar with that from Isothermal Titration Calorimetry (ITC) analysis (<xref rid="fig6" ref-type="fig">Fig. 6</xref>F). These data establish that SFN directly binds to p62.<fig id="fig6"><label>Fig. 6</label><caption><p><bold>SFN binds to the p62 protein. (A)</bold> Predicted binding mode of SFN with p62. <bold>(B)</bold> Predicted binding mode of SFN with SLC7A11. <bold>(C)</bold> OS cells were treated with PBS or SFN (20&#x000a0;&#x003bc;M) for 2&#x000a0;h and then heated at a gradient of 46&#x0223c;60&#x000a0;&#x000b0;C. Soluble p62 was detected by western blotting. <bold>(D)</bold> The binding of SFN to p62 was determined by DARTS approach. <bold>(E)</bold> The binding affinity between SFN (500,00&#x02013;1.53&#x000a0;nM) and p62 was determined using MST. <bold>(F)</bold> The thermogram and binding isotherm for the titration of SFN with p62. <bold>(G)</bold> The interactions of SFN with p62 mutants in OS cells were determined by DARTS approach. <bold>(H)</bold> OS cells were transfected with wild-type or mutant p62 for 24&#x000a0;h and were further treated with or without SFN. Then, the interaction between p62 and SLC7A11 was determined by western blotting. <bold>(I&#x02013;K)</bold> 143B and SJSA-1&#x000a0;cells were transfected with either p62-WT or p62 T5A mutant, followed by treatment with SFN (10&#x000a0;&#x003bc;M). ROS levels (I), GSH levels (J), and Liperfluo levels (K) were analyzed, respectively. &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0040">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig></p><p id="p0165">Furthermore, to validate the SFN-p62 interaction as well as its role in regulation of SLC7A11, mutation verification tests were conducted based the predicted binding sites of SFN at p62 Thr5 (T5) and Phe25 (F25) residues on p62 (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). With 143B cells transfected with wild-type p62 (WT), or p62 with T5A mutation (T5A), or p62 with F25Y mutation (F25Y), DARTS analysis showed that compared to WT and F25Y, T5A abolished the binding to SFN which did not protect this mutant from pronase-mediated degradation (<xref rid="fig6" ref-type="fig">Fig. 6</xref>G) in OS cells. IP analysis showed that SFN significantly increased the interaction between p62 and SLC7A11 in cells expressing WT or the F25Y mutant, but not in cells expressing the T5A mutant (<xref rid="fig6" ref-type="fig">Fig. 6</xref>H). Moreover, compared to WT and F25Y, the T5A mutant significantly reversed the downregulation of SLC7A11 in OS cells (<xref rid="fig6" ref-type="fig">Fig. 6</xref>H). Further measurement of ROS levels, GSH levels, and lipid peroxidation in cells demonstrated that the ferroptosis-inducing effects by SFN were abolished by T5A mutant (<xref rid="fig6" ref-type="fig">Fig. 6</xref>I&#x02013;K). These findings indicate that SFN binding to Thr5 of p62 promotes the interaction between p62 and SLC7A11, leading to the degradation of SLC7A11, thereby inducing ferroptosis.</p></sec><sec id="sec3.7"><label>3.7</label><title>SFN blocks OS progression through induction of ferroptosis <italic>in vivo</italic></title><p id="p0170">To assess the antitumor effects of SFN as well as the role of ferroptosis <italic>in vivo</italic>, two OS xenograft models were established. In the subcutaneous tumor model, following SFN treatment, the tumor volume and tumor weight were suppressed dose-dependently (<xref rid="fig7" ref-type="fig">Fig. 7</xref>A&#x02013;C). SFN treatment reduced GSH levels and increased MDA production, indicating the induction of ferroptosis (<xref rid="fig7" ref-type="fig">Fig. 7</xref>D and E). Additionally, immunohistochemistry (IHC) and western blot analyses of subcutaneous tumors revealed significantly lower expression levels of Ki67, SLC7A11, and GPX4, along with upregulated LC3B in the SFN-treated group (<xref rid="fig7" ref-type="fig">Fig. 7</xref>F and G). Co-IP experiment confirmed that SFN promoted the p62/SLC7A11 interaction in tumors (<xref rid="fig7" ref-type="fig">Fig. 7</xref>H). These data suggest that SFN exerts an antitumor effect in OS <italic>in vivo</italic>, which is associated with the induction of ferroptosis.<fig id="fig7"><label>Fig. 7</label><caption><p><bold>SFN blocks OS progression through induction of ferroptosis. (A)</bold> Representative photograph of tumor samples from each group. <bold>(B)</bold> Measurement of tumor volume. Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SEM. <bold>(C)</bold> Measurement of tumor weight. <bold>(D)</bold> Analysis of GSH levels in tumor tissues. <bold>(E)</bold> Analysis of MDA levels in tumor tissues. <bold>(F)</bold> IHC to determine the levels of Ki67, SLC7A11, GPX4, and LC3B in tumor tissues. Scale bar: 200&#x000a0;&#x003bc;m. <bold>(G)</bold> Measurement of protein expression levels of SLC7A11, GPX4, and LC3B in tumor tissues. <bold>(H)</bold> SFN induces the interaction of SLC7A11 and p62 <italic>in vivo</italic> assayed by Co-IP assay. <bold>(I)</bold> Representative photograph of tumor samples from each group. <bold>(J)</bold> Measurement of tumor volumes. Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SEM. <bold>(K)</bold> Analysis of GSH levels in tumor tissues. <bold>(L)</bold> Analysis of MDA levels in tumor tissues. <bold>(M)</bold> Lung tissues were harvested and subjected to H&#x00026;E staining. Quantification of the number of lung metastatic foci and lung metastasis rate in each group is shown. Scale bar: 500&#x000a0;&#x003bc;m &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><alt-text id="alttext0045">Fig. 7</alt-text><graphic xlink:href="gr7"/></fig></p><p id="p0175">To determine the dependency of ferroptosis in SFN-induced blockade of OS progression, an intratibial xenograft mouse model and the ferroptosis inhibitor Fer-1 were employed. Following treatment with SFN or/and Fer-1, the data showed that SFN significantly inhibited OS growth and Fer-1 notably attenuated the SFN-induced inhibition in the orthotopic xenograft models (<xref rid="fig7" ref-type="fig">Fig. 7</xref>I and J). Consistent with the subcutaneous tumor, the GSH levels and MDA production were decreased and increased, respectively (<xref rid="fig7" ref-type="fig">Fig. 7</xref>K and L). Similar with the data from subcutaneous tumor model, IHC and western blotting analyses revealed significantly lower expression levels of Ki67, SLC7A11, and GPX4 in the SFN treatment group (<xref rid="appsec2" ref-type="sec">Figs. S7A and B</xref>). Moreover, compared to the vehicle group, SFN treatment significantly reduced the number of lung metastatic foci, and Fer-1 partially reversed blockade of metastasis by SFN (<xref rid="fig7" ref-type="fig">Fig. 7</xref>M). Moreover, for the two <italic>in vivo</italic> models, no significant difference in body weight was observed between the control and SFN-treated groups (<xref rid="appsec2" ref-type="sec">Figs. S7C and D</xref>), and pathological examination of major organs (liver, kidney, heart, spleen, and lung) showed no evidence of toxicity associated with SFN treatment (<xref rid="appsec2" ref-type="sec">Fig. S7E</xref>). Collectively, these findings indicate that SFN blocks OS progression associated with its induction of ferroptosis <italic>in vivo</italic>.</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0180">OS is the most prevalent bone tumor in children and adolescents [<xref rid="bib45" ref-type="bibr">45</xref>], with a bimodal age distribution. Despite the use of chemotherapy (cisplatin, doxorubicin, and methotrexate), surgery, and radiation therapy, survival rates have not improved over the past four decades [<xref rid="bib46" ref-type="bibr">46</xref>]. Therefore, the search for safe and effective drugs, along with the identification of novel therapeutic targets for OS is of paramount importance.</p><p id="p0185">OS treatment faces several unique challenges, including high metastatic potential, especially to the lungs, and the development of drug resistance to conventional chemotherapy [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. Patients often experience severe side effects due to the high toxicity of current treatments. Therefore, treatment drugs must effectively inhibit tumor growth and metastasis, overcome drug resistance, minimize toxicity, and be compatible with combination therapies to enhance outcomes. Currently, natural plant extracts are considered an important source of anti-cancer agents due to their potential biological activity, reduced toxicity, and side effects compared to traditional chemotherapeutic drugs. In the present study, we report that SFN, an isothiocyanate derived from cruciferous vegetables, exhibits potent anti-tumor activities in OS cells by inducing ferroptosis both <italic>in vitro</italic> and <italic>in vivo</italic>. Mechanistically, SFN directly binds with p62, enhancing the interaction between p62 and SLC7A11, leading to SLC7A11 degradation through the autophagic lysosomal pathway.</p><p id="p0190">Ferroptosis, a recently discovered programmed cell death form, has emerged as a key focus in cancer research. It is primarily driven by lipid metabolism, GSH depletion, and dysregulated iron metabolism [<xref rid="bib49" ref-type="bibr">49</xref>]. The induction of ferroptosis has been recognized as a promising therapeutic strategy for cancer treatment. SFN offers several advantages in cancer treatment by inducing ferroptosis. Based on our findings, its ferroptosis-inducing activity indicates it selectively targets cancer cells that rely on iron metabolism and ROS generation, with minimal impact on normal cells, reducing harm to healthy tissues. Unlike traditional chemotherapy, its multi-target mechanism lowers the risk of drug resistance, especially in chemotherapy-resistant tumors. As a natural compound, SFN is well-tolerated with fewer side effects and toxicity [<xref rid="bib50" ref-type="bibr">50</xref>], which has been confirmed in our <italic>in vivo</italic> experiments. Additionally, it exhibits multiple anti-cancer mechanisms, such as antioxidant, anti-inflammatory, and cell cycle regulation, enhancing its therapeutic potential [<xref rid="bib51" ref-type="bibr">[51]</xref>, <xref rid="bib52" ref-type="bibr">[52]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>]. SLC7A11, a key regulator of ferroptosis that is often overexpressed in many cancers, plays a crucial role in promoting GSH biosynthesis and ferroptosis resistance [<xref rid="bib54" ref-type="bibr">54</xref>]. While its expression is regulated by multiple mechanisms, including transcriptional regulation by transcription factors [<xref rid="bib55" ref-type="bibr">55</xref>] epigenetic regulators [<xref rid="bib56" ref-type="bibr">56</xref>], and post-transcriptional regulatory mechanisms that modulate protein stability [<xref rid="bib57" ref-type="bibr">57</xref>,<xref rid="bib58" ref-type="bibr">58</xref>], subcellular localization [<xref rid="bib59" ref-type="bibr">59</xref>], and transporter activity [<xref rid="bib60" ref-type="bibr">60</xref>]. Our findings show that SFN downregulates SLC7A11 protein levels without affecting its mRNA transcription. This led us to investigate SFN's role in SLC7A11 protein degradation, which we found to occur through the lysosomal pathway, as the lysosomal inhibitor Baf-A1, but not the proteasome inhibitor MG132, blocked its degradation. Although the autophagic degradation of SLC7A11 has been reported [<xref rid="bib61" ref-type="bibr">61</xref>], our further studies revealed that the adapter protein p62 interacted with SLC7A11 and conferred its autophagic degradation. Moreover, SFN enhances the binding between p62 and SLC7A11, facilitating the selective autophagic degradation of SLC7A11. Importantly, we demonstrated that SFN directly binds to p62, driving the degradation of SLC7A11 through the lysosomal pathway.</p><p id="p0195">In two <italic>in vivo</italic> OS xenograft models, SFN's antitumor efficacy was confirmed, with the induction of ferroptosis observed, and the ferroptosis inhibitor Fer-1 partially rescuing this effect. These findings collectively underscore SFN's potential as a ferroptosis inducer and a promising therapeutic agent for OS treatment. For the treatment of OS in clinic, particularly for the combination treatment, SFN can enhance the therapeutic effect by synergizing with chemotherapy or immunotherapy, potentially overcoming drug resistance by targeting key ferroptosis-related molecules like SLC7A11. As a natural compound, SFN has lower toxicity compared to traditional chemotherapeutics, allowing for reduced doses of standard drugs and minimizing side effects. Additionally, SFN acts through different oncogenic pathways, complementing other treatments, and it can inhibit both tumor growth and metastasis, reducing the risk of recurrence. Thus, SFN holds promise as a valuable adjunct in OS therapy.</p></sec><sec id="sec5"><label>5</label><title>Conclusion</title><p id="p0200">In conclusion, we reveal that p62 play an important role for SLC7A11 autophagic degradation and our data suggest that SFN exerts its anti-osteosarcoma effects by inducing ferroptosis through targeting p62, leading to the degradation of SLC7A11 via the lysosomal pathway (<xref rid="fig8" ref-type="fig">Fig. 8</xref>). These findings provide new evidence for targeting SLC7A11 to treat cancer and offer the foundation for application of SFN as therapeutic agent for the treatment of OS.<fig id="fig8"><label>Fig. 8</label><caption><p><bold>Schematic illustration of SFN-induced ferroptosis thr</bold><bold>o</bold><bold>ugh downregulation of SLC7A11 by interacting with p62 in OS cells.</bold> In OS cells, SFN directly interacts with p62, promotes the association of p62 and SLC7A11, leading to autolysosomal degradation of SLC7A11, subsequently promoting ROS production, lipid peroxidation, ultimately inducing ferroptosis.</p></caption><alt-text id="alttext0050">Fig. 8</alt-text><graphic xlink:href="gr8"/></fig></p></sec><sec id="sec6"><title>CRediT authorship contribution statement</title><p id="p0205"><bold>Qiuming Zou:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Visualization, Validation, Methodology, Investigation, Formal analysis. <bold>Xiaofeng Zhou:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Validation, Methodology, Investigation, Formal analysis. <bold>Jianqin Lai:</bold> Validation, Resources, Methodology, Investigation, Data curation. <bold>Haixia Zhou:</bold> Methodology, Investigation. <bold>Jinxuan Su:</bold> Writing &#x02013; review &#x00026; editing, Methodology, Investigation. <bold>Zhijing Zhang:</bold> Validation, Methodology, Investigation. <bold>Xiaosong Zhuang:</bold> Visualization, Methodology, Investigation. <bold>Lili Liu:</bold> Methodology, Investigation. <bold>Ruijie Yuan:</bold> Software, Project administration. <bold>Sijia Li:</bold> Validation, Resources. <bold>Siyu Yang:</bold> Validation, Software. <bold>Xinyi Qu:</bold> Validation, Resources. <bold>Jiezhu Feng:</bold> Methodology, Investigation. <bold>Yongqi Liu:</bold> Project administration, Data curation. <bold>Zisheng Li:</bold> Visualization. <bold>Shiting Huang:</bold> Visualization. <bold>Zhi Shi:</bold> Resources, Methodology. <bold>Yu Yan:</bold> Supervision, Project administration, Conceptualization. <bold>Zhiming Zheng:</bold> Supervision, Project administration, Conceptualization. <bold>Wencai Ye:</bold> Supervision, Resources, Funding acquisition. <bold>Qi Qi:</bold> Writing &#x02013; review &#x00026; editing, Supervision, Resources, Funding acquisition, Conceptualization.</p></sec><sec sec-type="data-availability" id="sec7"><title>Data availability</title><p id="p0210">Data will be made available on request.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0215">The authors declare that they have no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Miller</surname><given-names>K.D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA: a cancer journal for clinicians</source><volume>69</volume><year>2019</year><fpage>7</fpage><lpage>34</lpage><comment>(2019)</comment><pub-id pub-id-type="pmid">30620402</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name></person-group><article-title>Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs</article-title><source>Cancer Lett.</source><volume>500</volume><year>2021</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">33359211</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Thanindratarn</surname><given-names>P.</given-names></name><name><surname>Dean</surname><given-names>D.C.</given-names></name><name><surname>Nelson</surname><given-names>S.D.</given-names></name><name><surname>Hornicek</surname><given-names>F.J.</given-names></name><name><surname>Duan</surname><given-names>Z.</given-names></name></person-group><article-title>Advances in immune checkpoint inhibitors for bone sarcoma therapy</article-title><source>Journal of bone oncology</source><volume>15</volume><year>2019</year><object-id pub-id-type="publisher-id">100221</object-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Bajpai</surname><given-names>J.</given-names></name><name><surname>Chandrasekharan</surname><given-names>A.</given-names></name><name><surname>Talreja</surname><given-names>V.</given-names></name><name><surname>Simha</surname><given-names>V.</given-names></name><name><surname>Chandrakanth</surname><given-names>M.V.</given-names></name><name><surname>Rekhi</surname><given-names>B.</given-names></name><name><surname>Khurana</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Vora</surname><given-names>T.</given-names></name><name><surname>Ghosh</surname><given-names>J.</given-names></name><name><surname>Banavali</surname><given-names>S.D.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'</article-title><source>European Journal of Cancer (Oxford, England : 1990)</source><volume>85</volume><year>2017</year><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">28888849</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Berhe</surname><given-names>S.</given-names></name><name><surname>Danzer</surname><given-names>E.</given-names></name><name><surname>Meyers</surname><given-names>P.A.</given-names></name><name><surname>Behr</surname><given-names>G.</given-names></name><name><surname>LaQuaglia</surname><given-names>M.P.</given-names></name><name><surname>Price</surname><given-names>A.P.</given-names></name></person-group><article-title>Unusual abdominal metastases in osteosarcoma</article-title><source>Journal of pediatric surgery case reports</source><volume>28</volume><year>2018</year><fpage>13</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">29085778</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>J.D.</given-names></name><name><surname>Dashwood</surname><given-names>R.H.</given-names></name><name><surname>Ho</surname><given-names>E.</given-names></name></person-group><article-title>Multi-targeted prevention of cancer by sulforaphane</article-title><source>Cancer Lett.</source><volume>269</volume><year>2008</year><fpage>291</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">18504070</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>P.</given-names></name><name><surname>Machado</surname><given-names>A.R.T.</given-names></name><name><surname>De Grandis</surname><given-names>R.A.</given-names></name><name><surname>Ribeiro</surname><given-names>D.L.</given-names></name><name><surname>Tuttis</surname><given-names>K.</given-names></name><name><surname>Morselli</surname><given-names>M.</given-names></name><name><surname>Aissa</surname><given-names>A.F.</given-names></name><name><surname>Pellegrini</surname><given-names>M.</given-names></name><name><surname>Antunes</surname><given-names>L.M.G.</given-names></name></person-group><article-title>Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells</article-title><source>Food Chem. Toxicol. : an international journal published for the British Industrial Biological Research Association</source><volume>136</volume><year>2020</year><object-id pub-id-type="publisher-id">111047</object-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wan</surname><given-names>X.</given-names></name><name><surname>Zhan</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name></person-group><article-title>Sulforaphane inhibits the growth of prostate cancer by regulating the microRNA-3919/DJ-1 axis</article-title><source>Front. Oncol.</source><volume>14</volume><year>2024</year><object-id pub-id-type="publisher-id">1361152</object-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Gasparello</surname><given-names>J.</given-names></name><name><surname>Gambari</surname><given-names>L.</given-names></name><name><surname>Papi</surname><given-names>C.</given-names></name><name><surname>Rozzi</surname><given-names>A.</given-names></name><name><surname>Manicardi</surname><given-names>A.</given-names></name><name><surname>Corradini</surname><given-names>R.</given-names></name><name><surname>Gambari</surname><given-names>R.</given-names></name><name><surname>Finotti</surname><given-names>A.</given-names></name></person-group><article-title>High levels of apoptosis are induced in the human colon cancer HT-29 cell line by Co-administration of sulforaphane and a peptide nucleic acid targeting miR-15b-5p</article-title><source>Nucleic Acid Therapeut.</source><volume>30</volume><year>2020</year><fpage>164</fpage><lpage>174</lpage></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Myzak</surname><given-names>M.C.</given-names></name><name><surname>Dashwood</surname><given-names>R.H.</given-names></name></person-group><article-title>Chemoprotection by sulforaphane: keep one eye beyond Keap1</article-title><source>Cancer Lett.</source><volume>233</volume><year>2006</year><fpage>208</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16520150</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Riedl</surname><given-names>M.A.</given-names></name><name><surname>Saxon</surname><given-names>A.</given-names></name><name><surname>Diaz-Sanchez</surname><given-names>D.</given-names></name></person-group><article-title>Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway</article-title><source>Clin. Immunol.</source><volume>130</volume><year>2009</year><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">19028145</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Kallifatidis</surname><given-names>G.</given-names></name><name><surname>Rausch</surname><given-names>V.</given-names></name><name><surname>Baumann</surname><given-names>B.</given-names></name><name><surname>Apel</surname><given-names>A.</given-names></name><name><surname>Beckermann</surname><given-names>B.M.</given-names></name><name><surname>Groth</surname><given-names>A.</given-names></name><name><surname>Mattern</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Kolb</surname><given-names>A.</given-names></name><name><surname>Moldenhauer</surname><given-names>G.</given-names></name></person-group><article-title>Sulforaphane targets pancreatic tumour-initiating cells by NF-&#x003ba;B-induced antiapoptotic signalling</article-title><source>Gut</source><volume>58</volume><year>2009</year><fpage>949</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">18829980</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>&#x0017b;ury&#x00144;</surname><given-names>A.</given-names></name><name><surname>Litwiniec</surname><given-names>A.</given-names></name><name><surname>Safiejko-Mroczka</surname><given-names>B.</given-names></name><name><surname>Klimaszewska-Wi&#x0015b;niewska</surname><given-names>A.</given-names></name><name><surname>Gagat</surname><given-names>M.</given-names></name><name><surname>Krajewski</surname><given-names>A.</given-names></name><name><surname>Gackowska</surname><given-names>L.</given-names></name><name><surname>Grzanka</surname><given-names>D.</given-names></name></person-group><article-title>The effect of sulforaphane on the cell cycle, apoptosis and expression of cyclin D1 and p21 in the A549 non-small cell lung cancer cell line</article-title><source>Int. J. Oncol.</source><volume>48</volume><year>2016</year><fpage>2521</fpage><lpage>2533</lpage><pub-id pub-id-type="pmid">27035641</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Park</surname><given-names>H.J.</given-names></name><name><surname>Moon</surname><given-names>D.O.</given-names></name></person-group><article-title>Sulforaphane sensitizes human breast cancer cells to paclitaxel-induced apoptosis by downregulating the NF-&#x003ba;B signaling pathway</article-title><source>Oncol. Lett.</source><volume>13</volume><year>2017</year><fpage>4427</fpage><lpage>4432</lpage><pub-id pub-id-type="pmid">28599444</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.V.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Lew</surname><given-names>K.L.</given-names></name><name><surname>Antosiewicz</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>D.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Watkins</surname><given-names>S.C.</given-names></name><name><surname>Johnson</surname><given-names>C.S.</given-names></name><name><surname>Trump</surname><given-names>D.L.</given-names></name></person-group><article-title>Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species</article-title><source>J. Biol. Chem.</source><volume>280</volume><year>2005</year><fpage>19911</fpage><lpage>19924</lpage><pub-id pub-id-type="pmid">15764812</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>S.J.</given-names></name><name><surname>Singletary</surname><given-names>K.W.</given-names></name><name><surname>Venema</surname><given-names>R.C.</given-names></name></person-group><article-title>Sulforaphane suppresses angiogenesis and disrupts endothelial mitotic progression and microtubule polymerization</article-title><source>Vasc. Pharmacol.</source><volume>46</volume><year>2007</year><fpage>77</fpage><lpage>84</lpage></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Jee</surname><given-names>H.G.</given-names></name><name><surname>Lee</surname><given-names>K.E.</given-names></name><name><surname>Kim</surname><given-names>J.B.</given-names></name><name><surname>Shin</surname><given-names>H.K.</given-names></name><name><surname>Youn</surname><given-names>Y.K.</given-names></name></person-group><article-title>Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro</article-title><source>Phytother Res.</source><volume>25</volume><year>2011</year><fpage>1623</fpage><lpage>1628</lpage><pub-id pub-id-type="pmid">21413088</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells</article-title><source>J. Nutr. Biochem.</source><volume>24</volume><year>2013</year><fpage>1062</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">23159064</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>M.</given-names></name><name><surname>Bieber</surname><given-names>M.</given-names></name><name><surname>Kraft</surname><given-names>P.</given-names></name><name><surname>Weber</surname><given-names>A.N.R.</given-names></name><name><surname>Stoll</surname><given-names>G.</given-names></name><name><surname>Schuhmann</surname><given-names>M.K.</given-names></name></person-group><article-title>The NLRP3 inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in mice</article-title><source>Brain Behav. Immun.</source><volume>92</volume><year>2021</year><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">33307174</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Alfieri</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Siow</surname><given-names>R.C.M.</given-names></name><name><surname>Cash</surname><given-names>D.</given-names></name><name><surname>Modo</surname><given-names>M.</given-names></name><name><surname>Duchen</surname><given-names>M.R.</given-names></name><name><surname>Fraser</surname><given-names>P.A.</given-names></name><name><surname>Williams</surname><given-names>S.C.R.</given-names></name><name><surname>Mann</surname><given-names>G.E.</given-names></name></person-group><article-title>Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke</article-title><source>Free Radic. Biol. Med.</source><volume>65</volume><year>2013</year><fpage>1012</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">24017972</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>S.J.</given-names></name><name><surname>Lemberg</surname><given-names>K.M.</given-names></name><name><surname>Lamprecht</surname><given-names>M.R.</given-names></name><name><surname>Skouta</surname><given-names>R.</given-names></name><name><surname>Zaitsev</surname><given-names>E.M.</given-names></name><name><surname>Gleason</surname><given-names>C.E.</given-names></name><name><surname>Patel</surname><given-names>D.N.</given-names></name><name><surname>Bauer</surname><given-names>A.J.</given-names></name><name><surname>Cantley</surname><given-names>A.M.</given-names></name><name><surname>Yang</surname><given-names>W.S.</given-names></name></person-group><article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title><source>Cell</source><volume>149</volume><year>2012</year><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">22632970</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Yagoda</surname><given-names>N.</given-names></name><name><surname>von Rechenberg</surname><given-names>M.</given-names></name><name><surname>Zaganjor</surname><given-names>E.</given-names></name><name><surname>Bauer</surname><given-names>A.J.</given-names></name><name><surname>Yang</surname><given-names>W.S.</given-names></name><name><surname>Fridman</surname><given-names>D.J.</given-names></name><name><surname>Wolpaw</surname><given-names>A.J.</given-names></name><name><surname>Smukste</surname><given-names>I.</given-names></name><name><surname>Peltier</surname><given-names>J.M.</given-names></name><name><surname>Boniface</surname><given-names>J.J.</given-names></name></person-group><article-title>RAS&#x02013;RAF&#x02013;MEK-dependent oxidative cell death involving voltage-dependent anion channels</article-title><source>Nature</source><volume>447</volume><year>2007</year><fpage>865</fpage><lpage>869</lpage></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>P.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name></person-group><article-title>Ferroptosis, a new form of cell death, and its relationships with tumourous diseases</article-title><source>J. Cell Mol. Med.</source><volume>21</volume><year>2017</year><fpage>648</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">27860262</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Latunde-Dada</surname><given-names>G.O.</given-names></name></person-group><article-title>Ferroptosis: role of lipid peroxidation, iron and ferritinophagy</article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><volume>1861</volume><year>2017</year><fpage>1893</fpage><lpage>1900</lpage><pub-id pub-id-type="pmid">28552631</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J.Y.</given-names></name><name><surname>Dixon</surname><given-names>S.J.</given-names></name></person-group><article-title>Mechanisms of ferroptosis</article-title><source>Cell. Mol. Life Sci.</source><volume>73</volume><year>2016</year><fpage>2195</fpage><lpage>2209</lpage><pub-id pub-id-type="pmid">27048822</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Kang</surname><given-names>R.</given-names></name><name><surname>Tang</surname><given-names>D.</given-names></name></person-group><article-title>Ferroptosis: process and function</article-title><source>Cell Death Differ.</source><volume>23</volume><year>2016</year><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">26794443</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Kang</surname><given-names>R.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name><name><surname>Tang</surname><given-names>D.</given-names></name></person-group><article-title>Broadening horizons: the role of ferroptosis in cancer</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>18</volume><year>2021</year><fpage>280</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">33514910</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Zeh</surname><given-names>H.J.</given-names></name><name><surname>Lotze</surname><given-names>M.T.</given-names></name><name><surname>Kang</surname><given-names>R.</given-names></name><name><surname>Tang</surname><given-names>D.</given-names></name></person-group><article-title>HSPA5 regulates ferroptotic cell death in cancer CellsFerroptosis in pancreatic cancer</article-title><source>Cancer Res.</source><volume>77</volume><year>2017</year><fpage>2064</fpage><lpage>2077</lpage><pub-id pub-id-type="pmid">28130223</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Koppula</surname><given-names>P.</given-names></name><name><surname>Sirohi</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name></person-group><article-title>BAP1 links metabolic regulation of ferroptosis to tumour suppression</article-title><source>Nat. Cell Biol.</source><volume>20</volume><year>2018</year><fpage>1181</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">30202049</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Kon</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>S.-J.</given-names></name><name><surname>Su</surname><given-names>T.</given-names></name><name><surname>Hibshoosh</surname><given-names>H.</given-names></name><name><surname>Baer</surname><given-names>R.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name></person-group><article-title>Ferroptosis as a p53-mediated activity during tumour suppression</article-title><source>Nature</source><volume>520</volume><year>2015</year><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">25799988</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Jennis</surname><given-names>M.</given-names></name><name><surname>Kung</surname><given-names>C.-P.</given-names></name><name><surname>Basu</surname><given-names>S.</given-names></name><name><surname>Budina-Kolomets</surname><given-names>A.</given-names></name><name><surname>Julia</surname><given-names>I.</given-names></name><name><surname>Leu</surname><given-names>J.</given-names></name><name><surname>Khaku</surname><given-names>S.</given-names></name><name><surname>Scott</surname><given-names>J.P.</given-names></name><name><surname>Cai</surname><given-names>K.Q.</given-names></name><name><surname>Campbell</surname><given-names>M.R.</given-names></name></person-group><article-title>An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model</article-title><source>Gene Dev.</source><volume>30</volume><year>2016</year><fpage>918</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">27034505</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Koppula</surname><given-names>P.</given-names></name><name><surname>Zhuang</surname><given-names>L.</given-names></name><name><surname>Gan</surname><given-names>B.</given-names></name></person-group><article-title>Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy</article-title><source>Protein &#x00026; cell</source><volume>12</volume><year>2021</year><fpage>599</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">33000412</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Koppula</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhuang</surname><given-names>L.</given-names></name><name><surname>Gan</surname><given-names>B.</given-names></name></person-group><article-title>Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer</article-title><source>Cancer Commun.</source><volume>38</volume><year>2018</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.S.</given-names></name><name><surname>SriRamaratnam</surname><given-names>R.</given-names></name><name><surname>Welsch</surname><given-names>M.E.</given-names></name><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Skouta</surname><given-names>R.</given-names></name><name><surname>Viswanathan</surname><given-names>V.S.</given-names></name><name><surname>Cheah</surname><given-names>J.H.</given-names></name><name><surname>Clemons</surname><given-names>P.A.</given-names></name><name><surname>Shamji</surname><given-names>A.F.</given-names></name><name><surname>Clish</surname><given-names>C.B.</given-names></name></person-group><article-title>Regulation of ferroptotic cancer cell death by GPX4</article-title><source>Cell</source><volume>156</volume><year>2014</year><fpage>317</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">24439385</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Friedmann Angeli</surname><given-names>J.P.</given-names></name><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Proneth</surname><given-names>B.</given-names></name><name><surname>Tyurina</surname><given-names>Y.Y.</given-names></name><name><surname>Tyurin</surname><given-names>V.A.</given-names></name><name><surname>Hammond</surname><given-names>V.J.</given-names></name><name><surname>Herbach</surname><given-names>N.</given-names></name><name><surname>Aichler</surname><given-names>M.</given-names></name><name><surname>Walch</surname><given-names>A.</given-names></name><name><surname>Eggenhofer</surname><given-names>E.</given-names></name></person-group><article-title>Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice</article-title><source>Nat. Cell Biol.</source><volume>16</volume><year>2014</year><fpage>1180</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">25402683</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name></person-group><article-title>The oxidative stress-inducible cystine/glutamate antiporter, system xc&#x02212;: cystine supplier and beyond</article-title><source>Amino Acids</source><volume>42</volume><year>2012</year><fpage>231</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">21409388</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>de la Vega</surname><given-names>M.R.</given-names></name><name><surname>Chapman</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>D.D.</given-names></name></person-group><article-title>NRF2 and the hallmarks of cancer</article-title><source>Cancer Cell</source><volume>34</volume><year>2018</year><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">29731393</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Badeaux</surname><given-names>A.I.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Emerging roles for chromatin as a signal integration and storage platform</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>14</volume><year>2013</year><fpage>211</fpage><lpage>224</lpage></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Parajuli</surname><given-names>N.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Lewno</surname><given-names>M.T.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Bedford</surname><given-names>L.</given-names></name><name><surname>Mayer</surname><given-names>R.J.</given-names></name></person-group><article-title>The calcineurin-TFEB-p62 pathway mediates the activation of cardiac macroautophagy by proteasomal malfunction</article-title><source>Circ. Res.</source><volume>127</volume><year>2020</year><fpage>502</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">32366200</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Tavana</surname><given-names>O.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name></person-group><article-title>The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11</article-title><source>Cancer Res.</source><volume>79</volume><year>2019</year><fpage>1913</fpage><lpage>1924</lpage><pub-id pub-id-type="pmid">30709928</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Ishimoto</surname><given-names>T.</given-names></name><name><surname>Nagano</surname><given-names>O.</given-names></name><name><surname>Yae</surname><given-names>T.</given-names></name><name><surname>Tamada</surname><given-names>M.</given-names></name><name><surname>Motohara</surname><given-names>T.</given-names></name><name><surname>Oshima</surname><given-names>H.</given-names></name><name><surname>Oshima</surname><given-names>M.</given-names></name><name><surname>Ikeda</surname><given-names>T.</given-names></name><name><surname>Asaba</surname><given-names>R.</given-names></name><name><surname>Yagi</surname><given-names>H.</given-names></name></person-group><article-title>CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc&#x02212; and thereby promotes tumor growth</article-title><source>Cancer Cell</source><volume>19</volume><year>2011</year><fpage>387</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">21397861</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Ursini</surname><given-names>F.</given-names></name><name><surname>Maiorino</surname><given-names>M.</given-names></name></person-group><article-title>Lipid peroxidation and ferroptosis: the role of GSH and GPx4</article-title><source>Free Radic. Biol. Med.</source><volume>152</volume><year>2020</year><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">32165281</pub-id>
</element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Lotze</surname><given-names>M.T.</given-names></name><name><surname>Zeh</surname><given-names>H.J.</given-names><suffix>3rd</suffix></name><name><surname>Kang</surname><given-names>R.</given-names></name><name><surname>Tang</surname><given-names>D.</given-names></name></person-group><article-title>Autophagy promotes ferroptosis by degradation of ferritin</article-title><source>Autophagy</source><volume>12</volume><year>2016</year><fpage>1425</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">27245739</pub-id>
</element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>M.A.</given-names></name><name><surname>Sooro</surname><given-names>M.A.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Autophagic regulation of p62 is critical for cancer therapy</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><year>2018</year></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>J.S.</given-names></name><name><surname>Davis</surname><given-names>L.E.</given-names></name></person-group><article-title>Osteosarcoma, chondrosarcoma, and chordoma</article-title><source>J. Clin. Oncol. : Official Journal of the American Society of Clinical Oncology</source><volume>36</volume><year>2018</year><fpage>188</fpage><lpage>193</lpage></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name></person-group><article-title>Advances on immunotherapy for osteosarcoma</article-title><source>Mol. Cancer</source><volume>23</volume><year>2024</year><fpage>192</fpage><pub-id pub-id-type="pmid">39245737</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>M.</given-names></name><name><surname>Tai</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Feng</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Osteosarcoma cells secrete CXCL14 that activates integrin &#x003b1;11&#x003b2;1 on fibroblasts to form a lung metastatic niche</article-title><source>Cancer Res.</source><volume>84</volume><year>2024</year><fpage>994</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">38295227</pub-id>
</element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>R.S.</given-names></name></person-group><article-title>Adjuvant and neoadjuvant chemotherapy for osteosarcoma: a historical perspective</article-title><source>Adv. Exp. Med. Biol.</source><volume>1257</volume><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">32483726</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.S.</given-names></name><name><surname>SriRamaratnam</surname><given-names>R.</given-names></name><name><surname>Welsch</surname><given-names>M.E.</given-names></name><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Skouta</surname><given-names>R.</given-names></name><name><surname>Viswanathan</surname><given-names>V.S.</given-names></name><name><surname>Cheah</surname><given-names>J.H.</given-names></name><name><surname>Clemons</surname><given-names>P.A.</given-names></name><name><surname>Shamji</surname><given-names>A.F.</given-names></name><name><surname>Clish</surname><given-names>C.B.</given-names></name><name><surname>Brown</surname><given-names>L.M.</given-names></name><name><surname>Girotti</surname><given-names>A.W.</given-names></name><name><surname>Cornish</surname><given-names>V.W.</given-names></name><name><surname>Schreiber</surname><given-names>S.L.</given-names></name><name><surname>Stockwell</surname><given-names>B.R.</given-names></name></person-group><article-title>Regulation of ferroptotic cancer cell death by GPX4</article-title><source>Cell</source><volume>156</volume><year>2014</year><fpage>317</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">24439385</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Iahtisham Ul</surname><given-names>H.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Awan</surname><given-names>K.A.</given-names></name><name><surname>Iqbal</surname><given-names>M.J.</given-names></name></person-group><article-title>Sulforaphane as a potential remedy against cancer: comprehensive mechanistic review</article-title><source>J. Food Biochem.</source><volume>46</volume><year>2022</year><object-id pub-id-type="publisher-id">e13886</object-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Shao</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Du</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Sulforaphane Activates a lysosome-dependent transcriptional program to mitigate oxidative stress</article-title><source>Autophagy</source><volume>17</volume><year>2021</year><fpage>872</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">32138578</pub-id>
</element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>C.</given-names></name><name><surname>Sadrieh</surname><given-names>L.</given-names></name><name><surname>Priyani</surname><given-names>A.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Hassan</surname><given-names>A.H.</given-names></name><name><surname>Hussain</surname><given-names>A.</given-names></name></person-group><article-title>Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells</article-title><source>Cancer epidemiology</source><volume>35</volume><year>2011</year><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">20956097</pub-id>
</element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Royston</surname><given-names>K.J.</given-names></name><name><surname>Paul</surname><given-names>B.</given-names></name><name><surname>Nozell</surname><given-names>S.</given-names></name><name><surname>Rajbhandari</surname><given-names>R.</given-names></name><name><surname>Tollefsbol</surname><given-names>T.O.</given-names></name></person-group><article-title>Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms</article-title><source>Exp. Cell Res.</source><volume>368</volume><year>2018</year><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29689276</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Koppula</surname><given-names>P.</given-names></name><name><surname>Zhuang</surname><given-names>L.</given-names></name><name><surname>Gan</surname><given-names>B.</given-names></name></person-group><article-title>Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy</article-title><source>Protein &#x00026; cell</source><volume>12</volume><year>2021</year><fpage>599</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">33000412</pub-id>
</element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Lewerenz</surname><given-names>J.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Albrecht</surname><given-names>P.</given-names></name><name><surname>Henke</surname><given-names>N.</given-names></name><name><surname>Noack</surname><given-names>R.</given-names></name><name><surname>Methner</surname><given-names>A.</given-names></name><name><surname>Maher</surname><given-names>P.</given-names></name></person-group><article-title>Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression</article-title><source>Cell Death Differ.</source><volume>19</volume><year>2012</year><fpage>847</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">22095285</pub-id>
</element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Koppula</surname><given-names>P.</given-names></name><name><surname>Sirohi</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Zhuang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Xiao</surname><given-names>Z.-D.</given-names></name><name><surname>Hung</surname><given-names>M.-C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Gan</surname><given-names>B.</given-names></name></person-group><article-title>BAP1 links metabolic regulation of ferroptosis to tumour suppression</article-title><source>Nat. Cell Biol.</source><volume>20</volume><year>2018</year><fpage>1181</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">30202049</pub-id>
</element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Ishimoto</surname><given-names>T.</given-names></name><name><surname>Nagano</surname><given-names>O.</given-names></name><name><surname>Yae</surname><given-names>T.</given-names></name><name><surname>Tamada</surname><given-names>M.</given-names></name><name><surname>Motohara</surname><given-names>T.</given-names></name><name><surname>Oshima</surname><given-names>H.</given-names></name><name><surname>Oshima</surname><given-names>M.</given-names></name><name><surname>Ikeda</surname><given-names>T.</given-names></name><name><surname>Asaba</surname><given-names>R.</given-names></name><name><surname>Yagi</surname><given-names>H.</given-names></name><name><surname>Masuko</surname><given-names>T.</given-names></name><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Kai</surname><given-names>K.</given-names></name><name><surname>Takahashi</surname><given-names>E.</given-names></name><name><surname>Imamura</surname><given-names>Y.</given-names></name><name><surname>Baba</surname><given-names>Y.</given-names></name><name><surname>Ohmura</surname><given-names>M.</given-names></name><name><surname>Suematsu</surname><given-names>M.</given-names></name><name><surname>Baba</surname><given-names>H.</given-names></name><name><surname>Saya</surname><given-names>H.</given-names></name></person-group><article-title>CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth</article-title><source>Cancer Cell</source><volume>19</volume><year>2011</year><fpage>387</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">21397861</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.-X.</given-names></name><name><surname>Li</surname><given-names>X.-J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Liang</surname><given-names>Y.-J.</given-names></name><name><surname>Zhou</surname><given-names>C.-X.</given-names></name><name><surname>Cao</surname><given-names>D.-X.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>G.-Q.</given-names></name><name><surname>He</surname><given-names>J.-R.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name></person-group><article-title>MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11</article-title><source>FEBS (Fed. Eur. Biochem. Soc.) Lett.</source><volume>585</volume><year>2011</year><fpage>1363</fpage><lpage>1367</lpage></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Goji</surname><given-names>T.</given-names></name><name><surname>Takahara</surname><given-names>K.</given-names></name><name><surname>Negishi</surname><given-names>M.</given-names></name><name><surname>Katoh</surname><given-names>H.</given-names></name></person-group><article-title>Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation</article-title><source>J. Biol. Chem.</source><volume>292</volume><year>2017</year><fpage>19721</fpage><lpage>19732</lpage><pub-id pub-id-type="pmid">29038291</pub-id>
</element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Lien</surname><given-names>E.C.</given-names></name><name><surname>Ghisolfi</surname><given-names>L.</given-names></name><name><surname>Geck</surname><given-names>R.C.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Toker</surname><given-names>A.</given-names></name></person-group><article-title>Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT</article-title><source>Sci. Signal.</source><volume>10</volume><year>2017</year></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S.</given-names></name><name><surname>Kimmelman</surname><given-names>A.C.</given-names></name></person-group><article-title>Autophagy is critical for cysteine metabolism in pancreatic cancer through regulation of SLC7A11</article-title><source>Autophagy</source><volume>17</volume><year>2021</year><fpage>1561</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">33985415</pub-id>
</element-citation></ref></ref-list><sec id="appsec1"><title>Abbreviations</title><p id="p0225">
<table-wrap position="anchor" id="undtbl1"><table frame="hsides" rules="groups"><tbody><tr><td align="left">CETSA</td><td align="left">Cellular thermal shift assay</td></tr><tr><td align="left">CHX</td><td align="left">C<bold>y</bold>cloheximide</td></tr><tr><td align="left">DARTS</td><td align="left">Drug affinity responsive target stability</td></tr><tr><td align="left">DCFH</td><td align="left">DA Dichlorodihydrofluorescein diacetate</td></tr><tr><td align="left">GPX4</td><td align="left">Glutathione peroxidase 4</td></tr><tr><td align="left">GSH</td><td align="left">Glutathione</td></tr><tr><td align="left">HE</td><td align="left">Hematoxylin and eosin</td></tr><tr><td align="left">IHC</td><td align="left">Immunohistochemitry</td></tr><tr><td align="left">ITC</td><td align="left">Isothermal Titration Calorimetry</td></tr><tr><td align="left">LPO</td><td align="left">Lipid peroxidation</td></tr><tr><td align="left">MST</td><td align="left">Microscale thermophoresis</td></tr><tr><td align="left">MTT</td><td align="left">Thiazolyl blue tetrazolium bromide</td></tr><tr><td align="left">OS</td><td align="left">Osteosarcoma</td></tr><tr><td align="left">p62</td><td align="left">Sequestosome-1</td></tr><tr><td align="left">ROS</td><td align="left">Reactive oxygen species</td></tr><tr><td align="left">SFN</td><td align="left">Sulforaphane</td></tr></tbody></table></table-wrap>
</p></sec><sec id="appsec2" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0230">The following is/are the supplementary data to this article.<supplementary-material content-type="local-data" id="mmc1"><caption><p>Supplementary figure 1. Effect of SFN alone or combined with different cell death inhibitors on the cell viability of OS cells. (A) Treatment of 143B and SJSA-1&#x000a0;cells with SFN with or without Nec-1 (10&#x000a0;&#x003bc;M) for 48&#x000a0;h, followed by cell viability detection. (B) Treatment of 143B and SJSA-1&#x000a0;cells with SFN with or without Z-VAD (10&#x000a0;&#x003bc;M) for 48&#x000a0;h, and subsequent cell viability detection. (C) Treatment of 143B and SJSA-1&#x000a0;cells with SFN with or without CQ (25&#x000a0;&#x003bc;M) for 48&#x000a0;h, and cell viability detection. (D) 143B and SJSA-1&#x000a0;cells were exposed to SFN with or without DFO (50&#x000a0;&#x003bc;M) for 48&#x000a0;h, and cell viability was assessed. (E) 143B and SJSA-1&#x000a0;cells were treated with SFN with or without Lip-1 (1&#x000a0;&#x003bc;M) for 48&#x000a0;h, and cell viability was evaluated. &#x02217;P&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;P&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><p>Supplementary figure 2. Effect of SLC7A11 on the proliferation and effect of SFN on the mRNA levels of SLC7A11 in OS cells. (A) 143B and SJSA-1&#x000a0;cells transfected SLC7A11. Cell proliferation was examined with MTT assay. (B) Relative mRNA levels of SLC7A11 were measured after SFN treatment. &#x02217;P&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;P&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><media xlink:href="mmc2.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><p>Supplementary figure 3. Effect of MG132 on SFN-induced degradation of SLC7A11. Following treatment with SFN and/or MG132, 143B (A) and SJSA-1 (B) cells were collected and analyzed by western blot analysis. &#x02217;P&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;P&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><media xlink:href="mmc3.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc4"><caption><p>Supplementary figure 4. Examination of the interactions between SLC7A11 and major autolysosomal proteins. With 143B cells, endogenous LC3B, ATG3, and LAMP1 were immunoprecipitated with SLC7A11 antibody and examined by western blot analysis.</p></caption><media xlink:href="mmc4.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc5"><caption><p>Supplementary figure 5. Effect of si-p62 on SFN-regulated SLC7A11 protein stability. (A, B) Following transfection with si-NC or si-p62, 143B (A) and SJSA-1 (B) cells were treated with CHX (50&#x000a0;&#x003bc;g/ml) and SFN (5&#x000a0;&#x003bc;M) for the indicated durations. The cells were then lysed and subjected to western blotting with the indicated antibodies.</p></caption><media xlink:href="mmc5.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc6"><caption><p>Supplementary figure 6. Effect of SFN on the interaction with SLC7A11 assayed by CESTA. 143B cells treated with PBS or SFN (20&#x000a0;&#x003bc;M) for 2&#x000a0;h and then heated at a gradient of 46&#x0223c;60&#x000a0;&#x000b0;C. Soluble SLC7A11 was detected by western blotting. &#x02217;P&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;P&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><media xlink:href="mmc6.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc7"><caption><p>Supplementary figure 7. Effect of SFN on OS xenograft <italic>in vivo</italic>. (A) IHC to determine the levels of Ki67, SLC7A11, and GPX4 in tumor tissues from intratibial xenograft mouse model. Scale bar: 200&#x000a0;&#x003bc;m. (B) The protein expression levels of SLC7A11 and GPX4 in tumor tissues intratibial xenograft mouse model. (C, D) The body weights of tumor bearing mice in subcutaneous (C) and intratibial (D) xenograft models were measured every other day. (E) H&#x00026;E staining of liver, kidney, heart, spleen, and lung from animals treated with vehicle control or 25 or 50&#x000a0;mg/kg of SFN. Scale bar: 100&#x000a0;&#x003bc;m &#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02217;&#x02217;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><media xlink:href="mmc7.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0220">This work was supported by the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100021171</institution-id><institution>Guangdong Basic and Applied Basic Research Foundation</institution></institution-wrap></funding-source> (2024A1515013108), the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs3">82293680</award-id>, <award-id award-type="grant" rid="gs3">82293680</award-id>, <award-id award-type="grant" rid="gs1">82321004</award-id>, <award-id award-type="grant" rid="gs3">82430108</award-id>, <award-id award-type="grant" rid="gs3">81973341</award-id>, <award-id award-type="grant" rid="gs3">82103185</award-id>), the <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012245</institution-id><institution>Science and Technology Projects in Guangzhou</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs6">202102070001</award-id>), the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100020593</institution-id><institution>fundamental research funds for the central universities</institution></institution-wrap></funding-source> (NO.<award-id award-type="grant" rid="gs7">21623109</award-id>), Qilu Sanitation and Health Leading Talent Cultivation Project (to Zhiming Zheng, 2020&#x02013;2025), and the Medical Joint Fund of <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004024</institution-id><institution>Jinan University</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs5">YXJC2022002</award-id>).</p></ack><fn-group><fn id="appsec3" fn-type="supplementary-material"><label>Appendix A</label><p id="p0235">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.redox.2024.103460" id="intref0030">https://doi.org/10.1016/j.redox.2024.103460</ext-link>.</p></fn></fn-group></back></article>